A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use.
See the abstract here
Related Topics
OCRA’s Advocate’s Corner: November 2025
Written by Chad Ramsey, Vice President, Policy, Ovarian Cancer Research Alliance Federal Update: Government Shutdown Ends — What It Means for the Cancer Community As you are no doubt aware, after 43 days, the federal government shutdown officially ended. On November 12, 2025, President Donald J. Trump signed the temporary funding bill passed by Congress, reopening … Continued
Ovarian Cancer Research Alliance Launches Center for Public Policy to Strengthen National Voice for Ovarian and Gynecologic Cancers
New policy hub builds on record of helping to secure billions in federal funding and training thousands of advocates, with expanded priorities and an interactive policy map New York, NY – [November 20, 2025] — Ovarian Cancer Research Alliance (OCRA) today announced the launch of its Center for Public Policy, a dedicated hub that reflects expanded policy … Continued
OCRA Invests More than $10.8 Million Toward Research, Part of $14.5 Million Commitment in 2025
In 2025, Ovarian Cancer Research Alliance (OCRA) invested more than $10.8 million toward scientific research—part of our $14.5 million commitment to strengthen the community through research, patient support, education and advocacy. This year’s investment represents OCRA’s broadest scope to date, encompassing not only our renowned grant programs but also global collaborations leveraging artificial intelligence (AI) … Continued